(Q72996887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

L P Boulet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M Laviolette

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Boucher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Knight

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Hébert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

K R Chapman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Allergy and Clinical Immunology

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

1 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

13-21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

Salmeterol: an inhaled beta 2-agonist with prolonged duration of action

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Long- versus short-acting beta 2-agonists. Implications for drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

A Single-dose Comparison of Inhaled Albuterol and Two Formulations of Salmeterol on Airway Reactivity in Asthmatic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Protection against allergen-induced asthma by salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Individual Comparisons by Ranking Methods

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

A critique of dosing strategies for beta-2 adrenergic agents and theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

The use of beta-agonists and the risk of death and near death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Regular vs as-needed inhaled salbutamol in asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

Regularly inhaled beta-agonists with steroids are not harmful in stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2897%2970295-1

7 January 2021

10.1016/S0091-6749(97)70295-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9003206%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference